INTENSITY THERAPEUTICS, INC.
Datakwaliteit: 83%
INTS
Nasdaq
Manufacturing
Chemicals
€ 5,57
▲
€ 0,07
(1,25%)
Marktkapitalisatie: 14,15 M
Prijs
€ 5,57
Marktkapitalisatie
14,15 M
Dagbereik
€ 5,51 — € 5,75
52-Weeksbereik
€ 4,63 — € 50,00
Volume
8.711
Openen € 5,63
50D / 200D Gem.
€ 7,43
25,08% below
50D / 200D Gem.
€ 8,41
33,78% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -9,23 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-246,78%
Onder sectorgemiddelde (-51,02%)
ROIC-197,29%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio3,60
Interest CoverageN/A
Waardering
PE (TTM)
-1,22
Boven sectorgemiddelde (-1,98)
P/B Ratio1,96
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,2 | -2,0 |
| P/B | 2,0 | 5,1 |
| ROE % | -246,8 | -51,0 |
| Net Margin % | — | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -11,61 M |
| ROE | -246,78% | ROA | -165,47% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -9,23 M |
| ROIC | -197,29% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3,60 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 5,91 M | Tangible Book Value | 7,22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,22 | Forward P/E | N/A |
| P/B Ratio | 1,96 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -65,26% | ||
| Market Cap | 14,15 M | Enterprise Value | 7,08 M |
| Per Share | |||
| EPS (Diluted TTM) | -8,56 | Revenue / Share | N/A |
| FCF / Share | -3,63 | OCF / Share | -3,63 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 79,55% |
| SBC-Adj. FCF | -11,27 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net Income | -11,61 M | -16,27 M | -10,54 M |
| EPS (Diluted) | -8,56 | -1,17 | -1,38 |
| Gross Profit | — | — | — |
| Operating Income | -11,97 M | -16,59 M | -8,32 M |
| EBITDA | — | — | — |
| R&D Expenses | 6,79 M | 10,50 M | 4,79 M |
| SG&A Expenses | — | — | — |
| D&A | — | — | — |
| Interest Expense | — | 0,0 | 305.000,0 |
| Income Tax | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 14,10 M | 4,78 M | 17,30 M |
| Total Liabilities | 2,23 M | 1,87 M | 4,13 M |
| Shareholders' Equity | 11,88 M | 2,92 M | 13,16 M |
| Total Debt | — | — | — |
| Cash & Equivalents | 11,92 M | 2,59 M | 8,56 M |
| Current Assets | 12,71 M | 3,36 M | 15,46 M |
| Current Liabilities | 2,15 M | 1,76 M | 3,96 M |
{"event":"ticker_viewed","properties":{"ticker":"INTS","listing_kind":"stock","pathname":"/stocks/ints","exchange":"Nasdaq","country":"US"}}